Abstract:Background: TNM stage alone cannot accurately predict the recurrence risk after curative resection of colorectal cancer (CRC) and the benefit of adjuvant chemotherapy for patients with stage II CRC. We assessed the value of prothrombin time (PT) and carcinoembryonic antigen (CEA) levels in recurrence prediction and whether the combination of PT and CEA levels and TNM stage can improve the accuracy in predicting postoperative recurrence of CRC.Methods: The coagulation indexes and tumor markers of 451 patients with CRC were analyzed retrospectively. Log-rank test, Cox proportional hazard regression model and Kaplan-Meier survival curve were used to analyze the value of these indexes in predicting postoperative recurrence in different TNM stage subgroups.Results: Preoperatively elevated levels of PT (≥12.65s) and CEA (≥ 10.175ng/ml) were independent factors affecting postoperative recurrence of CRC (p < 0.05 and p < 0.01, respectively). 451 CRC patients were divided into three groups according to preoperative levels of PT and CEA. The 5-year cumulative recurrence rate (CRR) and recurrence-free survival (RFS) differed significantly among the High-risk (PT ≥12.65s and CEA≥ 10.175ng/ml), Middle-risk (PT ≥12.65s or CEA≥ 10.175ng/ml), and Low-risk (PT < 12.65s and CEA < 10.175ng/ml) groups (p < 0.001). Patients in the High-risk group even have a significantly higher 5-year CRR and shorter RFS than those in TNM stage III (5-year CRR: 67.2% vs 48.7%, p < 0.001; RFS: 33.7 months vs 39.7 months, p < 0.001). PT and CEA as biomarkers for prognostic stratification showed that, in the subgroup of stage III, the 5-year CRR of the High-risk group was more than twice that of the Low-risk group (71.1% vs 31.8%, p < 0.001), and the RFS was 16.1 months shorter than that of the Low-risk group (30.1 vs 46.2, p < 0.001). In the subgroup of early-stage (stage I and II), the 5-year CRR in the High-risk group was more than 3 times higher than that in the Low-risk group (61.5%vs 18.4%; p < 0.001), and even higher than that in stage IIIA and B (61.5% vs 36.4%; p < 0.001) and similar to that in stage IIIC (61.5% vs 62.9%; p >0.05); moreover, the RFS of the High-risk group of early-stage was notably shorter than that of the Low-risk group (38.9 vs 53 months; p < 0.001) and even that of IIIA and B (38.9 vs 45.2 months; p < 0.05).Conclusion: Preoperatively elevated levels of PT and CEA were reliable predictors of postoperative high recurrence in CRC patients. Incorporation of PT and CEA levels to a recurrence prediction model with TNM stage can precisely identify a subgroup of CRC patients with -risk of recurrence in stage I-III, especially the risk of recurrence population in stage I and II.Funding Information: This work was supported by the National Natural Science Foundation of China (81502039), the Natural Science Foundation of Fujian Province (2016J01616 and 2020J011214), the Health and Family Planning Commission of Fujian Province for Youth Research Project (2015-2-49), the Scientific Research Foundation for Returned Scholars from Ministry of Human Resources and Social Security (2015142), and the Digestive Center of Xiamen University Foundation.Declaration of Interests: The authors had declared no conflict of interest.Ethics Approval Statement: This study was approved by the Ethics Review Committee of Zhongshan Hospital of Xiamen University and the informed consent of the patients was obtained.

A Recurrence‐predictive Model Based on Eight Genes and Tumor Mutational Burden/microsatellite Instability Status in Stage II/III Colorectal Cancer

Predictive and Prognostic Assessment Models for Tumor Deposit in Colorectal Cancer Patients with No Distant Metastasis

Recurrence risk stratification model for patients with stage I-III colorectal cancer based on clinicopathological and postoperative ctDNA predictors.

Circulating Tumor DNA As a Promising Biomarker of Relapse Risk for Stage II-III Colorectal Cancer.

Identification of Tumor Mutation Burden, Microsatellite Instability, and Somatic Copy Number Alteration Derived Nine Gene Signatures to Predict Clinical Outcomes in STAD.

Dissected subgroups predict the risk of recurrence of stage II colorectal cancer and select rational treatment

A Novel 9-Gene Signature for the Prediction of Postoperative Recurrence in Stage II/III Colorectal Cancer

Development and validation of postoperative circulating tumor DNA combined with clinicopathological risk factors for recurrence prediction in patients with stage I-III colorectal cancer

Postoperative circulating tumor DNA as markers of recurrence risk in stages II to III colorectal cancer

Individualized tumor-informed circulating tumor DNA analysis for molecular residual disease detection in predicting recurrence and efficacy of adjuvant chemotherapy in colorectal cancer.

A prognostic mutation panel for predicting cancer recurrence in stages II and III colorectal cancer

Combining PT and CEA Levels with the TNM Stage System to Identify Postoperative Recurrence Patients with Stage I-III Colorectal Cancer

Integration of genetic signature and TNM staging system for predicting the relapse of locally advanced colorectal cancer

An Immune, Stroma, and Epithelial–mesenchymal Transition‐related Signature for Predicting Recurrence and Chemotherapy Benefit in Stage II–III Colorectal Cancer

458P Circulating Tumor DNA Analysis Predicting Recurrence Risk in Patients with Stage I-III Colorectal Cancer

Prediction of postoperative recurrence by integrating preoperative ctDNA levels and tumor metastasis volume in patients (pts) with colorectal cancer (CRC) with resectable lung or liver metastasis.

Novel recurrently mutated genes and a prognostic mutation signature in colorectal cancer

Integrative Proteo-Genomic Analysis for Recurrent Survival Prognosis in Colon Adenocarcinoma

Use of circulating tumor DNA analysis to predict recurrence and need for adjuvant chemotherapy in stage I-IV colorectal cancer.

Development of a Nomogram for Predicting Survival in Microsatellite Stable Patients with Resected Colorectal Cancer

A Mutational Signature That Predicts Prognosis and Benefit of Immune Checkpoint Blockade in Colorectal Cancer